A key role in an effective blood management strategy

The risks and costs associated with homologous blood transfusion and its constantly decreasing worldwide availability have been widely documented.
Many health care providers and hospitals are now developing a Blood Management Strategy, a multidisciplinary approach to optimize the use of blood products, aiming to reduce the need for homologous blood, improve patient outcome and contain costs.
One of the key elements for a complete blood management strategy is autotransfusion, involving the collection, processing, and reinfusion of the patient’s own blood that is lost during the peri-operative period at the surgical site

Autotransfusion drives:

Maximum safety

It signicantly reduces the demand for homologous blood and prevents the risks involved in its transfusion:

  • Mistransfusion
  • Transfusion Related Acute Lung Injury (TRALI)
  • Systemic Infammatory Response Syndrome (SIRS)
  • Transfusion Related Immunomodulation (TRIM)
  • Immunosuppression

Significant cost reduction for the hospital

It provides fresh, autologous, vital RBCs to the patient eliminating the costs related to bank blood tranfusion:

  • The average total cost of transfusing a unit of homologous RBCs is USD$1,229*
  • No direct costs related to blood screening
  • Indirect long-term costs reduction: several studies show that the reinfusion of RBC’s recovered with autotransfusion improves post-operative outcome and decreases hospital stay and additional medical treatments.

* Shander, Aryeh, Hofmann Axel Et al. The true cost of red blood cell transfusions in surgical patients. 2008: Presented at the 50th Annual American Society of Hematology Meeting, The Moscone Center Poster Board III-127